Press release - 13/05/2024 Detecting respiratory infections: simply blow for diagnosis Professor Claudia Denkinger from Heidelberg University's Faculty of Medicine is leading the international collaborative project "BreathForDiagnosis". Researchers from Germany, Italy, South Africa and Romania are working with an industrial partner from Switzerland to develop user-friendly breath tests for the rapid diagnosis of respiratory infections such as tuberculosis.https://www.gesundheitsindustrie-bw.de/en/article/press-release/detecting-respiratory-infections-simply-blow-diagnosis
Press release - 07/05/2024 Intermittent fasting protects against liver inflammation and liver cancer / Drug partially mimics fasting effects Fatty liver disease often leads to chronic liver inflammation and can even result in liver cancer. Scientists from the German Cancer Research Center (DKFZ) and the University of Tuebingen have now shown in mice that intermittent fasting can halt this development. https://www.gesundheitsindustrie-bw.de/en/article/press-release/intermittent-fasting-protects-against-liver-inflammation-and-liver-cancer-drug-partially-mimics-fasting-effects
Press release - 06/05/2024 Research under high pressure Why 3,000 bars are needed to take a comprehensive look at a protein: Konstanz researchers Frederic Berner and Michael Kovermann present a new high-pressure spectroscopy method to unravel the properties of proteins' native structures.https://www.gesundheitsindustrie-bw.de/en/article/press-release/research-under-high-pressure
Press release - 03/05/2024 Newly discovered mechanism of T-cell control can interfere with cancer immunotherapies Activated T cells that carry a certain marker protein on their surface are controlled by natural killer cells. In this way, the body presumably curbs destructive immune reactions. Researchers now discovered that NK cells can impair the effect of cancer therapies with immune checkpoint inhibitors in this way. They could also be responsible for the rapid decline of therapeutic CAR-T cells. https://www.gesundheitsindustrie-bw.de/en/article/press-release/newly-discovered-mechanism-t-cell-control-can-interfere-cancer-immunotherapies
Press release - 25/04/2024 Diamond dust shines bright in Magnetic Resonance Imaging An unexpected discovery surprised a scientist at the Max Planck Institute for Intelligent Systems in Stuttgart: nanometer-sized diamond particles, which were intended for a completely different purpose, shone brightly in a magnetic resonance imaging experiment – much brighter than the actual contrast agent, the heavy metal gadolinium. Could diamond dust one day become a novel contrast agent used for MRI? https://www.gesundheitsindustrie-bw.de/en/article/press-release/diamond-dust-shines-bright-magnetic-resonance-imaging
Press release - 24/04/2024 CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat. Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary second-generation mRNA backbone. https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-announces-start-combined-phase-12-study-avian-influenza-h5n1-development-collaboration-gsk
Press release - 24/04/2024 Strengthening the healthcare sector in the state: BIOPRO Baden-Württemberg networks itself strategically at a European level BIOPRO has been supporting Baden-Württemberg as a healthcare location for many years and provides important incentives for its further development. The state company has been a member of the Council of European Bioregions (CEBR) network since April 2024. Within the CEBR, BIOPRO aims to network with European cooperation partners in order to provide even better support for the innovative capacity of the healthcare industry in Baden-Württemberg.https://www.bio-pro.de/en/information/press-release/strengthening-healthcare-sector-state-biopro-baden-wuerttemberg-networks-itself-strategically-european-level
Event - 16/10/2024 - 17/10/2024 Diagnostics-4-Future Conference 2024 Konstanz, Germany, Conference https://www.gesundheitsindustrie-bw.de/en/event/diagnostics-4-future-conference-2024
Press release - 19/04/2024 Electrified bacteria PhD student at Furtwangen University develops method for faster determination of antibiotic resistance. The increase in antibiotic-resistant pathogens and the associated treatment, which is a major problem in public healthcare facilities, is the subject of a research project at Furtwangen University.https://www.gesundheitsindustrie-bw.de/en/article/press-release/bakterien-unter-strom
Press release - 18/04/2024 Additional partnership in medical technology: Bosch and R-Biopharm to strengthen Vivalytic analysis platform The market for medical technology is innovative, dynamic, and growing. Bosch sees medical technology as a strategic growth field and intends to expand its Bosch Healthcare Solutions subsidiary, based in Waiblingen. Bosch has now entered into a new partnership with the German diagnostics solutions company R-Biopharm. This partnership will be focused on Bosch’s universal, fully automated Vivalytic molecular diagnostic analysis platform. https://www.gesundheitsindustrie-bw.de/en/article/press-release/additional-partnership-medical-technology-bosch-and-r-biopharm-strengthen-vivalytic-analysis-platform
Press release - 18/04/2024 Collagen: Researchers at the NMI decipher how it works in medical treatment Collagen has been used in ophthalmology since the 1990s, particularly in the treatment of corneal defects. However, why and how this technique works was only known in theory. Researchers at the NMI Natural and Medical Sciences Institute in Reutlingen led by Lu Fan have found the necessary evidence and can now reliably explain how this technique works.https://www.gesundheitsindustrie-bw.de/en/article/press-release/collagen-researchers-nmi-decipher-how-it-works-medical-treatment
Press release - 17/04/2024 Cell Biology: Molecular Code Stimulates Pioneer Cells to Build Blood Vessels in the Body Cardiovascular diseases, including stroke and myocardial infarction, are the world's leading causes of mortality, accounting for over 18 million deaths a year. A team of KIT researchers has now identified a new cell type in blood vessels responsible for vascular growth. This discovery may allow for novel therapeutic strategies to treat ischemic cardiovascular diseases, i.e. diseases that are caused by reduced or absent blood flow.https://www.gesundheitsindustrie-bw.de/en/article/press-release/zellbiologie-molekularer-code-regt-pionierzellen-zum-aufbau-von-blutgefaessen-im-koerper
Event - 22/05/2024 - 24/05/2024 The MedTech Forum 2024 Vienna, Austria, Conference https://www.gesundheitsindustrie-bw.de/en/event/medtech-forum-2024
Press release - 11/04/2024 How the body switches out of “fight” mode Study in Nature unlocks how cortisone inhibits inflammation Cortisone and other related glucocorticoids are extremely effective at curbing excessive immune reactions. But previously, astonishingly little was known about how they exactly do that. A team of researchers from Charité – Universitätsmedizin Berlin, Uniklinikum Erlangen and Ulm University have now explored the molecular mechanism of action in greater detail. https://www.gesundheitsindustrie-bw.de/en/article/press-release/wie-der-kampfmodus-im-koerper-beendet-wird-studie-nature-entschluesselt-wie-kortison-entzuendungen-daempft
Press release - 10/04/2024 Cyber Valley grants 500K to CELL’n’ROLL via 2023 Innovation Fellowship Program Pioneering cutting-edge diagnostic systems for the detection of complex diseases: Cyber Valley is pleased to announce it has awarded funding of 500K EUR to the CELL’n’ROLL team through the 2023 Cyber Valley Innovation Fellowship program, funded by the Carl-Zeiss-Stiftung.https://www.gesundheitsindustrie-bw.de/en/article/press-release/cyber-valley-grants-500k-cellnroll-2023-innovation-fellowship-program
Press release - 10/04/2024 Growth through medical technology: Bosch and Randox invest heavily in the Vivalytic analysis platform With its Vivalytic analysis platform, Bosch has set itself the goal of making fast and highly precise diagnostics accessible at the point of care – and aims to use molecular diagnostics to become a leading provider in the market by 2030. To achieve this, Bosch has now agreed on a strategic partnership with Randox Laboratories Ltd., a leading diagnostic and medical technology company.https://www.gesundheitsindustrie-bw.de/en/article/press-release/growth-through-medical-technology-bosch-and-randox-invest-heavily-vivalytic-analysis-platform
Press release - 02/04/2024 Precise localization of miniature robots and surgical instruments inside the body In the medicine of the future, tiny robots will navigate independently through tissue and medical instruments will indicate their position inside the body during surgery. Both require doctors to be able to localize and control the devices precisely and in real time. Scientists from the German Cancer Research Center (DKFZ) have now described a signaling method based on an oscillating magnet that can significantly improve such medical applications.https://www.gesundheitsindustrie-bw.de/en/article/press-release/precise-localization-miniature-robots-and-surgical-instruments-inside-body
Epifadin from the nasal microbiome - 28/03/2024 From the nose: novel antibiotic substance discovered Antibiotics are becoming an increasingly blunt weapon against infectious diseases. The number of (multi-)resistant germs has been rising rapidly for years and even reserve antibiotics no longer work. Researchers at the University of Tübingen have now isolated a completely new antibiotic substance called epifadin from the microbiome of the human nose. It is effective against many different bacteria - including the dangerous hospital MRSA.https://www.gesundheitsindustrie-bw.de/en/article/news/nose-novel-antibiotic-substance-discovered
Press release - 27/03/2024 Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101 Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the treatment of multiple myeloma to its lead candidate HDP-101. Heidelberg Pharma is investigating the candidate in a clinical Phase I/IIa study for the treatment of relapsed/refractory multiple myeloma (RRMM).https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-pharma-granted-orphan-drug-designation-fda-its-proprietary-atac-candidate-hdp-101
Press release - 22/03/2024 Decoding the shared genetic toolkit for male sex determination Researchers from the Max Planck Institute for Biology Tübingen broke new ground by demonstrating that an HMG-box gene in brown algae is crucial for determining male sex. This breakthrough significantly expands our understanding of sex-determination mechanisms in eukaryotic organisms. Until now, master sex-determination genes had been identified in only a select number of animals and plants. https://www.gesundheitsindustrie-bw.de/en/article/press-release/decoding-shared-genetic-toolkit-male-sex-determination
Press release - 22/03/2024 New Emmy Noether junior research group for biological data science An Emmy Noether junior research group at Heidelberg University is investigating how to gain new insights into fundamental biological mechanisms from large-scale molecular data sets. Led by Junior Professor Dr Britta Velten, it has started work at the Centre for Organismal Studies and the Interdisciplinary Center for Scientific Computing. https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-emmy-noether-junior-research-group-biological-data-science
Press release - 14/03/2024 Planned NMI spin-off: immuneAdvice successful in start-up competition Does our therapeutic approach work against cancer? The answer to this question can make the difference between life and death - and is still difficult to answer. A team from the NMI Natural and Medical Sciences Institute at the University of Tübingen and the Werner Siemens Imaging Center Tübingen has developed a technique for observing immune cells. https://www.gesundheitsindustrie-bw.de/en/article/press-release/geplante-nmi-ausgruendung-immuneadvice-bei-startup-wettbewerb-erfolgreich
Press release - 14/03/2024 Machine learning classifier accelerates the development of cellular immunotherapies Making a personalised T cell therapy for cancer patients currently takes at least six months; scientists at the German Cancer Research Center (DKFZ) and the University Medical Center Mannheim have shown that the laborious first step of identifying tumor-reactive T cell receptors for patients can be replaced with a machine learning classifier that halves this time.https://www.gesundheitsindustrie-bw.de/en/article/press-release/machine-learning-classifier-accelerates-development-cellular-immunotherapies
Press release - 14/03/2024 Next milestone in the treatment of liver tumors and acute and chronic liver diseases The results of a Tuebingen-led study raise hope that a newly developed drug could herald a new era in oncological liver surgery and transplantation. The drug could even have the potential to significantly improve the treatment of acute and chronic liver diseases. The drug candidate "HRX-215" is a so-called MKK4 inhibitor, i.e. the drug inhibits the MKK4 protein found in liver cells and thus leads to an increase in the regeneration of…https://www.gesundheitsindustrie-bw.de/en/article/press-release/next-milestone-treatment-liver-tumors-and-acute-and-chronic-liver-diseases
Stem cell research - 14/03/2024 Using organoids to gain a better clinical understanding of pancreatic cancer Prof. Dr. Alexander Kleger carries out translational research at Ulm University Hospital to gain a better understanding of pancreatic ductal adenocarcinoma (PDAC) and develop individualised treatments. He and his team are using organoid models and stem cell-based systems and have succeeded in simultaneously cultivating all three main cell types of the pancreas from pluripotent stem cells.https://www.gesundheitsindustrie-bw.de/en/article/news/using-organoids-gain-better-clinical-understanding-pancreatic-cancer